Most recent edit on 2006-12-30 07:38:52 by KathyFromEngland
Additions:
CategoryFrequentlyAskedQuestions
Edited on 2006-10-19 10:48:26 by KathyFromEngland
Additions:
Categories
CategoryGeneralOstomy
Deletions:
Categories
CategoryOstomyInfo
Edited on 2006-07-27 13:29:41 by KathyFromEngland
No differences.
Edited on 2006-07-27 13:29:16 by KathyFromEngland
Additions:
About a Peristomal Hernia
Positive Results For Permacol? As A Prophylactic Treatment For Parastomal Hernias And As A Treatment For Anal Fistulae
16 Jul 2006
At the Annual Meeting of the ACPGBI (Association of Coloproctology of Great Britain & Ireland) held in Gateshead, 3-6 July, Tissue Science Laboratories plc, the medical devices company specialising in human tissue replacement and repair products, presented supportive evidence from two pilot studies - the first, an application of Permacol? as a treatment for parastomal hernias and the second, for the treatment of anal fistulae.
There are over 1.4 million existing stomas in the US and Europe, and approximately 160,000 new stomas created per annum. Parastomal herniation (the formation of a hernia beside the stoma) is a persistent and troublesome problem with an approximate occurrence rate of up to 50%. The first study presented looked at the efficacy of Permacol? as a prophylactic to prevent parastomal herniation. The study comprised 20 patients - 10 treated prophylactically with Permacol?. 3 out of 10 patients without Permacol? were found to have experienced parastomal hernias; none of the patients with the Permacol? prophylactic showed herniation. Contrary to current treatments such as synthetic mesh, there were no complications related to infection or related to the proximity to the bowel associated with the use of Permacol?. A full scale randomized controlled prophylactic study is now underway.
The second pilot study aimed to assess the short-term safety, feasibility and efficacy of using Permacol?, either as a solid implanted seton (a thread of material that is passed through the fistula) or as fibres suspended in fibrin glue, to heal idiopathic anal fistulae whilst preserving continence. This has traditionally been treated by surgery, but more recently fibrin glue is being used with variable success. Its drawbacks include that it is broken down relatively rapidly and it fails to eradicate secondary tracts and acute sepsis in advance. The results of the study using Permacol? revealed that at three months post-operation, no patient in either the collagen implant or collagen glue mixture groups had experienced symptoms of continence disturbance or acute perianal sepsis, which are usually common with this condition. Also, sphincter integrity and anorectal movement were unchanged. The results of this study suggest that Permacol? is a safe, potentially effective sphincter-conserving technique, and the results allow an extension of the study.
Stephen Bloor, Technical Director, said: ?We are pleased to report further successful studies for Permacol?, which has proven to offer many advantages such as greater comfort, durability and without the many side effects of current treatments. The results of these studies offer further supportive examples for the multiple applications of Permacol?.?
Background on TSL
Founded in 1995, with headquarters in Aldershot, Hampshire, TSL is a medical technology company specialising in tissue repair and replacement with a proprietary sheet product, derived from porcine dermis, called Permacol?. TSL has launched successfully different formulations of the product and built a development pipeline that addresses the large and fast growing surgical implant market. The Company floated in November 2001 and is listed on the Alternative Investment Market (LSE: TSL).
TSL has a family of products based on the same core technology. Each product has been adapted, with unique properties, to make it suitable for use in different applications, including urology/gynaecology, complex and recurrent hernia repair, shoulder rotator cuff repair and head and face repair and reconstruction. The Company has signed distribution agreements with CR Bard Inc (urology/gynaecology - worldwide), Zimmer Inc (orthopaedic - worldwide) and Porex Surgical Inc (head and face - US and Canada). Further variations of the sheet and injectable forms of Permacol? are being developed. For more information on TSL, please visit the website at http://www.tissuescience.com∞.
Background on Permacol?
Permacol? was developed at Dundee and Cambridge Universities over a 20-year time period. The key to the Permacol? concept lies in it collagen technology which uses non-reconstituted porcine dermal collagen, very similar in structure to human tissue. Non-collagenous material, except elastin, is removed by the TSL manufacturing process. The remaining collagen, which retains its original 3-D structural architecture, is stabilised by a patented cross-linking process. The result is a non-reconstituted, non-allergenic, collagen implant which is resistant to biodegradation, is recognised and accepted by the body, and is able to provide a long-term support for the in-growth of new tissue and its associated blood supply.
http://www.tissuescience.com∞
http://www.medilexicon.com/medicalnews.php?newsid=47383∞
Deletions:
About a PeristomalHernia
Edited on 2006-07-27 08:07:29 by KathyFromEngland
Additions:
About a Peristomal Hernia
Deletions:
Edited on 2006-07-27 08:07:20 by KathyFromEngland
Additions:
Categories
CategoryOstomyInfo
Oldest known version of this page was edited on 2006-07-26 14:10:03 by KathyFromEngland []
Page view:
About a PeristomalHernia
Contents
Definition
About a
PeristomalHernia
Treatment
Further Information
Latest Research
Definition
Treatment
Further Information
Latest Research
Page was generated in 0.2991 seconds